Immunomic Therapeutics Announces Clinical Trial of ITI-3000 for the Treatment of Merkel Cell Carcino

ROCKVILLE, Md.--(BUSINESS WIRE)--#MCC--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein) -mediated nucleic acid-based immunotherapy, today announced its first Phase 1 clinical study evaluating ITI-3000 in p...

Related Keywords

Rockville ,Maryland ,United States ,University Of Washington ,Washington ,Seattle ,Nancy Lillie ,Melissa Kemp ,David Koelle ,Paul Nghiem ,Fred Hutchinson Cancer Center ,Therapeutics Inc ,Head Of Dermatology At University Washington ,University Of Washington School Medicine ,Pharmajet Inc ,Immunomic Therapeutics Inc ,Immunomic Therapeutics ,Lysosome Associated Membrane Protein ,Washington School ,Song Park ,Dose Limiting Toxicities ,Serious Adverse Reactions ,Intracellular Targeted Expression ,Needle Free Injection System ,William Hearl ,Chief Executive Officer ,Jet Needle Free Systems ,Jet Media ,